Suppr超能文献

体内肿瘤内在因素的会聚鉴定和干扰对癌症免疫的影响。

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

机构信息

System Biology Institute, Integrated Science & Technology Center, 850 West Campus Drive, West Haven, CT 06516, USA; Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA; Center for Cancer Systems Biology, Integrated Science & Technology Center, 850 West Campus Drive, West Haven, CT 06516, USA; MCGD Program, Yale University, 333 Cedar Street, New Haven, CT 06510, USA.

System Biology Institute, Integrated Science & Technology Center, 850 West Campus Drive, West Haven, CT 06516, USA; Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA; Center for Cancer Systems Biology, Integrated Science & Technology Center, 850 West Campus Drive, West Haven, CT 06516, USA.

出版信息

Cell Syst. 2019 Feb 27;8(2):136-151.e7. doi: 10.1016/j.cels.2019.01.004. Epub 2019 Feb 20.

Abstract

The genetic makeup of cancer cells directs oncogenesis and influences the tumor microenvironment. In this study, we massively profiled genes that functionally drive tumorigenesis using genome-scale in vivo CRISPR screens in hosts with different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to robustly outgrow as tumors in fully immunocompetent hosts. Functional interrogation showed that Prkar1a loss greatly altered the transcriptome and proteome involved in inflammatory and immune responses as well as extracellular protein production. Single-cell transcriptomic profiling and flow cytometry analysis mapped the tumor microenvironment of Prkar1a mutant tumors and revealed the transcriptomic alterations in host myeloid cells. Taken together, our data suggest that tumor-intrinsic mutations in Prkar1a lead to drastic alterations in the genetic program of cancer cells, thereby remodeling the tumor microenvironment.

摘要

癌细胞的基因构成指导肿瘤发生,并影响肿瘤微环境。在这项研究中,我们使用具有不同免疫能力的宿主中的全基因组规模体内 CRISPR 筛选,大规模分析了那些在功能上驱动肿瘤发生的基因。作为这些筛选的一个收敛命中,Prkar1a 突变细胞能够在完全免疫能力的宿主中作为肿瘤强劲地生长。功能询问表明,Prkar1a 的缺失极大地改变了参与炎症和免疫反应以及细胞外蛋白产生的转录组和蛋白质组。单细胞转录组谱分析和流式细胞术分析绘制了 Prkar1a 突变肿瘤的肿瘤微环境,并揭示了宿主髓样细胞中的转录组改变。总之,我们的数据表明,Prkar1a 中的肿瘤内在突变导致癌细胞遗传程序的剧烈改变,从而重塑肿瘤微环境。

相似文献

2
A CRISPR Platform for Targeted In Vivo Screens.用于体内靶向筛选的CRISPR平台。
Methods Mol Biol. 2023;2614:397-409. doi: 10.1007/978-1-0716-2914-7_24.
3
Cancer CRISPR Screens In Vivo.体内癌症CRISPR筛选
Trends Cancer. 2018 May;4(5):349-358. doi: 10.1016/j.trecan.2018.03.002. Epub 2018 Mar 30.
7
CRISPR-Cas9 for cancer therapy: Opportunities and challenges.CRISPR-Cas9 用于癌症治疗:机遇与挑战。
Cancer Lett. 2019 Apr 10;447:48-55. doi: 10.1016/j.canlet.2019.01.017. Epub 2019 Jan 23.
8
High-content CRISPR screening in tumor immunology.高内涵 CRISPR 筛选在肿瘤免疫学中的应用。
Front Immunol. 2022 Nov 21;13:1041451. doi: 10.3389/fimmu.2022.1041451. eCollection 2022.
10
Engineered CRISPR Systems for Next Generation Gene Therapies.用于下一代基因治疗的工程化CRISPR系统
ACS Synth Biol. 2017 Sep 15;6(9):1614-1626. doi: 10.1021/acssynbio.7b00011. Epub 2017 Jun 7.

引用本文的文献

2
Applications of CRISPR technology in cellular immunotherapy.CRISPR 技术在细胞免疫治疗中的应用。
Immunol Rev. 2023 Nov;320(1):199-216. doi: 10.1111/imr.13241. Epub 2023 Jul 14.
8
Tumor immunology CRISPR screening: present, past, and future.肿瘤免疫学 CRISPR 筛选:现状、过去和未来。
Trends Cancer. 2022 Mar;8(3):210-225. doi: 10.1016/j.trecan.2021.11.009. Epub 2021 Dec 15.

本文引用的文献

6
Correction of aberrant growth preserves tissue homeostasis.纠正异常生长可维持组织内稳态。
Nature. 2017 Aug 17;548(7667):334-337. doi: 10.1038/nature23304. Epub 2017 Aug 2.
7
Identification of essential genes for cancer immunotherapy.癌症免疫治疗关键基因的鉴定。
Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.
8
Novel PRKAR1A mutation in Carney complex with cardiac myxoma.
Pediatr Int. 2017 Jul;59(7):840-841. doi: 10.1111/ped.13302.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验